ADMS - Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth
- Adamas Pharmaceuticals reported their Q1 earnings with a slight beat on EPS and a slight miss on revenue. GOCOVRI continues to report impressive growth despite a lackluster launch.
- Despite the commercial progress, the ADMS share price remains suppressed. It looks as if the Street is waiting to see if and when the company will clear a profit.
- I reloaded on top of my core position in hopes Adamas will break even around 2024, but I willing to unload due to the ticker being in purgatory.
For further details see:
Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth